CTOs on the Move

Cutanix Corporation

www.cutanix.com

 
Cutanix Corporation is a Franksville, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.cutanix.com
  • 4133 Courtney Rd Ste 10
    Franksville, WI USA 53126
  • Phone: 888.751.7546

Executives

Name Title Contact Details

Similar Companies

Qvin

Take control of your health in the most natural way possible.

Adventus Group

Adventus Group is a Freeport, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

OWKIN

OWKIN builds mathematical models and algorithms that can interpret omics, visual data, biostatistics and patient profiles like never before. With OWKIN, patients directly benefit with more effective treatments.

Tyme

TYME, Inc. is a pharmaceutical company focused on creating medicines that specialize in using the body’s immune system to treat diseases. The body has the ability to fight off major diseases and heal itself. Tyme is researching a mechanism that it believes may work alongside the body’s immune system to fight Stage IV Metastatic Cancer. Tyme hopes to provide a novel compound for physicians to use in a treatment regimen for patients fighting six major cancers (breast, lung, prostrate, gastric, esophageal and pancreatic cancers) responsible for 62% of the annual cancer deaths in the United States. The SM-88, Tyme’s proprietary compound, is a novel compound that has the potential to alter defenses to oxidative stress and increase free radical availability to the cancer cell. SM-88 is designed to penetrate the living cancer cells and introduce multiple mechanisms to kill the cell. Inducing transfer of electrons in the cancer cells may allow catalyzed external free radicals to react and stress the cell. SM-88 is a combination of low dose agents used for non-cancer treatment.

BioTheryX

BioTheryX is a clinical-stage biopharmaceutical company focused on restoring protein homeostasis through protein modulation, including protein degradation as well as multi-kinase inhibition, to develop treatments that extend and improve the quality-of-life of patients with life-threatening diseases.